Skip to main content

Table 1 Search strategy

From: Immunotherapy with check-point inhibitors (CPI) in adult malignancies: a protocol for the systematic review of the quality of economic analyses

Search term
 1. Immunotherapy/
 2. immunotherap*.ti,ab.
 3. immuno therap*.ti,ab.
 4. immuno-oncology.ti,ab.
 5. immunooncology.ti,ab.
 6. immuno oncology.ti,ab.
 7. immuno-therap*.ti,ab.
 8. chemoimmunotherap*.ti,ab.
 9. chemo-immunotherap*.ti,ab
 10. checkpoint inhibitor*.ti,ab.
 11. check-point inhibitor*.ti,ab.
 12. check point inhibitor*.ti,ab.
 13. check-point block*.ti,ab.
 14. checkpoint block*.ti,ab.
 15. check point block*.ti,ab.
 16. check-point therap*.ti,ab.
 17. checkpoint therap*.ti,ab.
 18. check point therap*.ti,ab.
 19. pd-l1.ti,ab.
 20. pd-1.ti,ab.
 21. ctla-4.ti,ab.
 22. exp CTLA-4 Antigen/
 23. Cytotoxic T-Lymphocyte Associated Antigen 4.ti,ab.
 24. Cytotoxic T-Lymphocyte Antigen 4.ti,ab.
 25. exp Programmed cell death 1 receptor/
 26. Programmed cell death 1 receptor.ti,ab.
 27. Programmed cell death 1 protein.ti,ab.
 28. Pd 1 protein.ti,ab.
 29. PDCD1 protein.ti,ab
 30. CD279 antigen.ti,ab.
 31. nivolumab.ti,ab.
 32. Opdivo.ti,ab.
 33. pembrolizumab.ti,ab.
 34. Keytruda.ti,ab.
 35. durvalumab.ti,ab.
 36. Imfinzi.ti,ab.
 37. tremelimumab.ti,ab.
 38. Exp ipilimumab/
 39. Yervoy.ti,ab.
 40. atezolizumab.ti,ab.
 41. Tecentriq.ti,ab.
 42. avelumab.ti,ab.
 43. Bavencio.ti,ab.
 44. Economics/
 45. exp Costs and Cost Analysis/
 46. Economics, Medical/
 47. Economics, Nursing/
 48. Economics, Pharmaceutical/
 49. exp Economics, Hospital/
 50. exp “Fees and Charges”/
 51. exp Budgets/
 52. economic*.ti,ab.
 53. cost*.ti,ab.
 54. pric*.ti,ab.
 55. fees.ti,ab.
 56. pharmacoeconomic.ti,ab.
 57. pharmaco-economic.ti,ab.
 58. expendit*.ti,ab.
 59. (value adj2 mone*).ti,ab.
 60. exp models, economic/
 61. exp Neoplasms/
 62. cancer*.ti,ab.
 63. neoplas*.ti,ab.
 64. tumor.ti,ab.
 65. tumor.ti,ab.
 66. malignan*.ti,ab.
 67. or/1–43
 68. or/44–60
 69. or/61–66
 70. 67 and 68 and 69